Bod Australia Ltd ( (AU:BOD) ) has issued an announcement.
Bod Science Limited has entered into a Deed of Company Arrangement with Biortica Agrimed Limited, which includes a Share Purchase Agreement to acquire Biortica’s shares. The completion of this arrangement is contingent on meeting certain conditions, including shareholder approvals and compliance with ASX requirements. The company reported a net cash inflow from operating activities of $42k for Q3 FY2025, with customer receipts increasing significantly due to new product introductions. The arrangement and financial updates reflect Bod’s strategic efforts to stabilize and grow its operations amid ongoing corporate restructuring.
More about Bod Australia Ltd
Bod Science Limited is a cannabis-focused drug development and product innovation company. It is dedicated to advancing research and development with a clear clinical trial pathway to commercialize and deliver premium, scientifically proven, and trusted products for patients and consumers. The company has partnerships with large corporate entities and collaborations with leading research organizations to further the use of cannabis-related medicines with therapeutic indications.
YTD Price Performance: 20.0%
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$4.26M
See more data about BOD stock on TipRanks’ Stock Analysis page.